These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20847643)

  • 1. Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization.
    Nakano K; Ishiguro T; Konishi H; Tanaka M; Sugimoto M; Sugo I; Igawa T; Tsunoda H; Kinoshita Y; Habu K; Orita T; Tsuchiya M; Hattori K; Yamada-Okabe H
    Anticancer Drugs; 2010 Nov; 21(10):907-16. PubMed ID: 20847643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.
    Nakano K; Orita T; Nezu J; Yoshino T; Ohizumi I; Sugimoto M; Furugaki K; Kinoshita Y; Ishiguro T; Hamakubo T; Kodama T; Aburatani H; Yamada-Okabe H; Tsuchiya M
    Biochem Biophys Res Commun; 2009 Jan; 378(2):279-84. PubMed ID: 19022220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.
    Ishiguro T; Sugimoto M; Kinoshita Y; Miyazaki Y; Nakano K; Tsunoda H; Sugo I; Ohizumi I; Aburatani H; Hamakubo T; Kodama T; Tsuchiya M; Yamada-Okabe H
    Cancer Res; 2008 Dec; 68(23):9832-8. PubMed ID: 19047163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.
    Zhu AX; Gold PJ; El-Khoueiry AB; Abrams TA; Morikawa H; Ohishi N; Ohtomo T; Philip PA
    Clin Cancer Res; 2013 Feb; 19(4):920-8. PubMed ID: 23362325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathological analyses of the antitumor activity of anti-glypican-3 antibody (GC33) in human liver cancer xenograft models: The contribution of macrophages.
    Takai H; Kato A; Kinoshita Y; Ishiguro T; Takai Y; Ohtani Y; Sugimoto M; Suzuki M
    Cancer Biol Ther; 2009 May; 8(10):930-8. PubMed ID: 19276671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma.
    Ikeda M; Ohkawa S; Okusaka T; Mitsunaga S; Kobayashi S; Morizane C; Suzuki I; Yamamoto S; Furuse J
    Cancer Sci; 2014 Apr; 105(4):455-62. PubMed ID: 24521523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma.
    Yorita K; Takahashi N; Takai H; Kato A; Suzuki M; Ishiguro T; Ohtomo T; Nagaike K; Kondo K; Chijiiwa K; Kataoka H
    Liver Int; 2011 Jan; 31(1):120-31. PubMed ID: 20964802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A humanized monoclonal antibody constructed from intronless expression vectors targets human hepatocellular carcinoma cells.
    Chan KT; Cheng SC; Xie H; Xie Y
    Biochem Biophys Res Commun; 2001 Jun; 284(1):157-67. PubMed ID: 11374885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
    Wu H; Nie Y; Huse WD; Watkins JD
    J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and characterization of a high-affinity humanized SM5-1 monoclonal antibody.
    Li B; Wang H; Zhang D; Qian W; Hou S; Shi S; Zhao L; Kou G; Cao Z; Dai J; Guo Y
    Biochem Biophys Res Commun; 2007 Jun; 357(4):951-6. PubMed ID: 17451647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glypican-3 antibodies: a new therapeutic target for liver cancer.
    Feng M; Ho M
    FEBS Lett; 2014 Jan; 588(2):377-82. PubMed ID: 24140348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
    Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
    Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
    Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma.
    Sun L; Gao F; Gao Z; Ao L; Li N; Ma S; Jia M; Li N; Lu P; Sun B; Ho M; Jia S; Ding T; Gao W
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the three-dimensional structures of a humanized and a chimeric Fab of an anti-gamma-interferon antibody.
    Fan ZC; Shan L; Goldsteen BZ; Guddat LW; Thakur A; Landolfi NF; Co MS; Vasquez M; Queen C; Ramsland PA; Edmundson AB
    J Mol Recognit; 1999; 12(1):19-32. PubMed ID: 10398393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma.
    Bell MM; Gutsche NT; King AP; Baidoo KE; Kelada OJ; Choyke PL; Escorcia FE
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33374953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-classical binding of a polyreactive α-type anti-idiotypic antibody to B cells.
    Hernández T; de Acosta CM; López-Requena A; Moreno E; Alonso R; Fernández-Marrero Y; Pérez R
    Mol Immunol; 2010; 48(1-3):98-108. PubMed ID: 20952071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humanization of an anti-human IL-6 mouse monoclonal antibody glycosylated in its heavy chain variable region.
    Sato K; Ohtomo T; Hirata Y; Saito H; Matsuura T; Akimoto T; Akamatsu K; Koishihara Y; Ohsugi Y; Tsuchiya M
    Hum Antibodies Hybridomas; 1996; 7(4):175-83. PubMed ID: 9140729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants.
    De Pascalis R; Gonzales NR; Padlan EA; Schuck P; Batra SK; Schlom J; Kashmiri SV
    Clin Cancer Res; 2003 Nov; 9(15):5521-31. PubMed ID: 14654532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
    Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
    Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.